PS81. A MEGA-ANALYSIS OF FIXED-DOSE TRIALS REVEALS DOSE-DEPENDENCY, A RAPID ONSET OF ACTION AND A RESPECTABLE EFFECT SIZE FOR THE SYMPTOM-REDUCING EFFECTS OF SSRIs IN ADULT MAJOR DEPRESSION

s | 27 was taking 1.26 ± 0.51 types of ADs and the AAP augmentation group 1.31 ± 0.54, plus 1.06 ± 0.19 AAPs. At 2 weeks, response was observed in 11 patients (35.48%) in the AD group and 18 patients (35.29%) in the AAP augmentation group (χ2 = 0, p = 1). At week 8, 16 (52.44%) and 27 patients (52.94%) achieved remission (χ2 = 0, p = 1), respectively. However, baseline HDRS-17 total scores were 18.55 ± 5.73 and 22.39 ± 6.14 (t = 2.819, p < 0.01) for the AD and AAP groups, respectively. Conclusion: Compared with AD treatment, AAP augmentation did not show a more rapid response nor greater remission rates. Considering that the AAP augmentation group had more severe depressive symptoms at baseline, AAP augmentation may be effective in severe MDD. PS79 Gender differences in sunshine increased antidepressant placebo effect Joël Gailledreau, Béatrice Gailledreau,Nathalie Desbonnet, Philippe